Literature DB >> 23879279

Oral contraceptive use and the ECG: evidence of an adverse QT effect on corrected QT interval.

Tara Sedlak1, Chrisandra Shufelt, Carlos Iribarren, Liisa L Lyon, C Noel Bairey Merz.   

Abstract

BACKGROUND: A prolonged corrected QT (QTc) interval is a marker for an increased risk of sudden cardiac death. We evaluated the relationship between oral contraceptive (OC) use, type of OC, and QTc interval.
METHODS: We identified 410,782 ECGs performed at Northern California Kaiser Permanente on female patients between 15 and 53 years from January, 1995 to June, 2008. QT was corrected for heart rate using log-linear regression. OC generation (first, second and third) was classified by increasing progestin androgenic potency, while the fourth generation was classified as antiandrogenic.
RESULTS: Among 410,782 women, 8.4% were on OC. In multivariate analysis after correction for comorbidities, there was an independent shortening effect of OCs overall (slope = -0.5 ms; SE = 0.12, P < 0.0002). Users of first and second generation progestins had a significantly shorter QTc than nonusers (P < 0.0001), while users of fourth generation had a significantly longer QTc than nonusers (slope = 3.6 ms, SE = 0.35, P < 0.0001).
CONCLUSION: Overall, OC use has a shortening effect on the QTc. Shorter QTc is seen with first and second generation OC while fourth generation OC use has a lengthening effect on the QTc. Careful examination of adverse event rates in fourth generation OC users is needed. ©2013, Wiley Periodicals, Inc.

Entities:  

Keywords:  QT; hormones

Mesh:

Substances:

Year:  2013        PMID: 23879279      PMCID: PMC3725654          DOI: 10.1111/anec.12050

Source DB:  PubMed          Journal:  Ann Noninvasive Electrocardiol        ISSN: 1082-720X            Impact factor:   1.468


  21 in total

1.  Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology.

Authors:  N Krieger
Journal:  Am J Public Health       Date:  1992-05       Impact factor: 9.308

2.  Effects of hormone replacement therapy on QT interval.

Authors:  J A Larsen; R H Tung; R Sadananda; J J Goldberger; G Horvath; M A Parker; A H Kadish
Journal:  Am J Cardiol       Date:  1998-10-15       Impact factor: 2.778

3.  Drug-induced QT prolongation in women during the menstrual cycle.

Authors:  I Rodriguez; M J Kilborn; X K Liu; J C Pezzullo; R L Woosley
Journal:  JAMA       Date:  2001-03-14       Impact factor: 56.272

4.  Clinical assessment of drug-induced QT prolongation in association with heart rate changes.

Authors:  Fabrice Extramiana; Pierre Maison-Blanche; Marie-José Cabanis; Catherine Ortemann-Renon; Philippe Beaufils; Antoine Leenhardt
Journal:  Clin Pharmacol Ther       Date:  2005-04       Impact factor: 6.875

5.  Repolarization measures and their relation to sex hormones in postmenopausal women with cardiovascular disease receiving hormone replacement therapy.

Authors:  Karolina Nowinski; Ulla Pripp; Kjell Carlström; Britt-Marie Landgren; Karin Schenck-Gustafsson; Lennart Bergfeldt
Journal:  Am J Cardiol       Date:  2002-11-15       Impact factor: 2.778

6.  QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest.

Authors:  A Algra; J G Tijssen; J R Roelandt; J Pool; J Lubsen
Journal:  Circulation       Date:  1991-06       Impact factor: 29.690

7.  Estrogen and progestin use and the QT interval in postmenopausal women.

Authors:  Alan H Kadish; Philip Greenland; Marian C Limacher; William H Frishman; Sandra A Daugherty; Janice B Schwartz
Journal:  Ann Noninvasive Electrocardiol       Date:  2004-10       Impact factor: 1.468

8.  A prospective evaluation of the risk of QT prolongation with hormone replacement therapy: the atherosclerosis risk in communities study.

Authors:  Mercedes R Carnethon; Mary S Anthony; Wayne E Cascio; Aaron R Folsom; Pentti M Rautaharju; Duanping Liao; Gregory W Evans; Gerardo Heiss
Journal:  Ann Epidemiol       Date:  2003-08       Impact factor: 3.797

9.  Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein.

Authors:  Karine Lacut; Emmanuel Oger; Grégoire Le Gal; Marie-Thérèse Blouch; Jean-François Abgrall; Véronique Kerlan; Pierre-Yves Scarabin; Dominique Mottier
Journal:  Thromb Haemost       Date:  2003-07       Impact factor: 5.249

10.  Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy.

Authors:  François Laliberté; Katherine Dea; Mei Sheng Duh; Kristijan H Kahler; Melanie Rolli; Patrick Lefebvre
Journal:  Menopause       Date:  2011-10       Impact factor: 3.310

View more
  7 in total

Review 1.  Women-specific factors to consider in risk, diagnosis and treatment of cardiovascular disease.

Authors:  Ronée E Harvey; Kirsten E Coffman; Virginia M Miller
Journal:  Womens Health (Lond)       Date:  2015-03

2.  The effect of therapeutic and supratherapeutic oral doses of nomegestrol acetate (NOMAC)/17β-estradiol (E2) on QTcF intervals in healthy women: results from a randomized, double-blind, placebo- and positive-controlled trial.

Authors:  Pieter-Jan de Kam; Jacqueline van Kuijk; Otilia Lillin; Teun Post; Torben Thomsen
Journal:  Clin Drug Investig       Date:  2014-06       Impact factor: 2.859

3.  Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors.

Authors:  Virginie Grouthier; Benedicte Lebrun-Vignes; Andrew M Glazer; Philippe Touraine; Christian Funck-Brentano; Antoine Pariente; Carine Courtillot; Anne Bachelot; Dan M Roden; Javid J Moslehi; Joe-Elie Salem
Journal:  Heart       Date:  2018-05-02       Impact factor: 5.994

4.  Association of Oral Contraceptives With Drug-Induced QT Interval Prolongation in Healthy Nonmenopausal Women.

Authors:  Joe-Elie Salem; Pauline Dureau; Anne Bachelot; Marine Germain; Pascal Voiriot; Bruno Lebourgeois; David-Alexandre Trégouët; Jean-Sébastien Hulot; Christian Funck-Brentano
Journal:  JAMA Cardiol       Date:  2018-09-01       Impact factor: 14.676

5.  Oral contraceptive use and the risk of cardiac events in patients with long QT syndrome.

Authors:  Abeer Abu-Zeitone; Derick R Peterson; Bronislava Polonsky; Scott McNitt; Arthur J Moss
Journal:  Heart Rhythm       Date:  2014-04-13       Impact factor: 6.343

Review 6.  Contraceptive Strategies in Women With Heart Failure or With Cardiac Transplantation.

Authors:  Anjli Maroo; Johnny Chahine
Journal:  Curr Heart Fail Rep       Date:  2018-06

Review 7.  Sexual Dimorphisms, Anti-Hormonal Therapy and Cardiac Arrhythmias.

Authors:  Virginie Grouthier; Melissa Y Y Moey; Estelle Gandjbakhch; Xavier Waintraub; Christian Funck-Brentano; Anne Bachelot; Joe-Elie Salem
Journal:  Int J Mol Sci       Date:  2021-02-02       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.